Full Press Release Details
Aprea Therapeutics Announces $3.1 Million Private
Placement Priced At-The-Market Under Nasdaq Rules
Financing from new and existing healthcare focused
The proceeds are expected to extend the Company's
cash runway into Q1 2027, with potential inflection points anticipated in its clinical programs during that period
Pa, Dec. 9, 2025 (GLOBE NEWSWIRE) - Aprea Therapeutics, Inc. (Nasdaq: APRE) ("Aprea", or the "Company"),
a clinical-stage biopharmaceutical company developing innovative treatments that exploit specific cancer cell vulnerabilities while minimizing
damage to healthy cells, today announced that it has entered into a securities purchase agreement with new and existing healthcare focused
investors and certain insiders of the Company to sell an aggregate of 2,623,023 shares of common stock (or pre-funded warrants in-lieu
thereof), together with warrants to purchase up to an aggregate 2,623,023 shares of common stock, in a private placement priced at-the-market
under Nasdaq rules (the "Offering"). The combined effective offering price for each share of common stock (or pre-funded
warrant in-lieu thereof) and accompanying warrant to be issued is $1.165. The warrants to be issued will have an exercise price of $1.04
per share, will be exercisable immediately upon issuance, and will expire on the five-year anniversary of the earlier of the effectiveness
date of the registration statement covering the resale of the securities purchased in the Offering and the date the shares underlying
the warrants are eligible for resale under Rule 144.
The gross proceeds to the Company from the Offering
are estimated to be approximately $3.1 million before deducting the placement agent's fees and other estimated Offering expenses.
The Company intends to use the upfront net proceeds from the private placement for general corporate purposes and for research and development
expenses. The Company believes the aggregate net proceeds from the Offering will be sufficient to fund the Company into 2027 based on
current projections. The Offering is expected to close on or about December 10, 2025, subject to the satisfaction of customary closing
Maxim Group LLC is acting as the sole placement
agent in connection with the Offering.
The offer and sale of the foregoing securities
are being made in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the "Securities
Act"), and/or Regulation D promulgated thereunder, and the securities have not been registered under the Securities Act or applicable
state securities laws. Accordingly, the securities may not be reoffered or resold in the United States except pursuant to an effective
registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities
laws. The Company has agreed to file a registration statement with the Securities and Exchange Commission registering the resale of the
securities purchased in the private placement.
This press release does not constitute an offer
to sell or the solicitation of an offer to buy the securities, nor shall there be any sale of the securities in any state in which such
offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state. Any
offering of the securities under the resale registration statement will only be made by means of a prospectus.
Aprea is pioneering a new approach to treat cancer by exploiting vulnerabilities associated with cancer cell mutations. This
approach was developed to kill tumors but to minimize the effect on normal, healthy cells, decreasing the risk of toxicity that is frequently
associated with chemotherapy and other treatments. Aprea's technology has potential applications across multiple cancer types, enabling
it to target a range of tumors, including ovarian, endometrial, colorectal, prostate, and breast cancers.
company's lead programs are APR-1051, an oral, small-molecule inhibitor of WEE1 kinase, and ATRN-119, a small molecule ATR inhibitor,
both in clinical development for solid tumor indications. For more information, please visit the company website at www.aprea.com.
Forward-Looking Statement
Certain information contained in this press
release includes "forward-looking statements", within the meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended related to our study analyses, clinical trials, regulatory submissions,
and projected cash position. We may, in some cases use terms such as "future," "predicts," "believes,"
"potential," "continue," "anticipates," "estimates," "expects," "plans,"
"intends," "targeting," "confidence," "may," "could," "might,"
"likely," "will," "should" or other words that convey uncertainty of the future events or outcomes
to identify these forward-looking statements. Our forward-looking statements are based on current beliefs and expectations of our management
team and on information currently available to management that involve risks, potential changes in circumstances, assumptions, and uncertainties.
All statements contained in this press release other than statements of historical fact are forward-looking statements, including statements
regarding our ability to develop, commercialize, and achieve market acceptance of our current and planned products and services, our research
and development efforts, including timing considerations and other matters regarding our business strategies, use of capital, results
of operations and financial position, and plans and objectives for future operations. Any or all of the forward-looking statements may
turn out to be wrong or be affected by inaccurate assumptions we might make or by known or unknown risks and uncertainties. These forward-looking
statements are subject to risks and uncertainties including, without limitation, the risk that the proposed private placement and the
transactions described herein may not be completed in a timely manner or at all, the failure to realize the anticipated benefits of the
private placement and related transactions, market and other conditions, as well as other factors described under "Risk Factors,"
"Management's Discussion and Analysis of Financial Condition and Results of Operations" and elsewhere in the documents
we file with the U.S. Securities and Exchange Commission. For all these reasons, actual results and developments could be materially
different from those expressed in or implied by our forward-looking statements. You are cautioned not to place undue reliance on these
forward-looking statements, which are made only as of the date of this press release. We undertake no obligation to update such forward-looking
statements for any reason, except as required by law.